Skip to search formSkip to main contentSkip to account menu

BMS-911543

Known as: JAK2 Inhibitor BMS-911543 
An orally available small molecule targeting a subset of Janus-associated kinase (JAK) with potential antineoplastic activity. JAK2 inhibitor BMS… 
National Institutes of Health

Related topics

Related topics

1 relation
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
In Vitro Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance - Implications for Targeted Therapy
Introduction Treatment-resistant acute lymphoblastic leukemia (ALL) remains a significant clinical issue. Recently, genomic… 
2015
2015
A UHPLC-MS/MS bioanalytical assay for the determination of BMS-911543, a JAK2 inhibitor, in human plasma.
2014
2014
Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells
Imatinib Mesylate (IM) and other tyrosine kinase inhibitor (TKI) therapies have had a major impact on the treatment of chronic… 
2014
2014
Limited Efficacy of BMS-911543 in a Murine Model of JAK2V617F Myeloproliferative Neoplasm
Activation of JAK2, frequently as a result of the JAK2V617F mutation, is a characteristic feature of the classical… 
2014
2014
BMS-911543 inhibits viability of tumor and stromal cells and limits disease progression in genetically engineered mice with pancreatic cancer
Pancreatic cancer (PCa) is resistant to cytotoxic therapies, and the profound immune suppressive nature of this disease renders… 
Highly Cited
2012
Highly Cited
2012
Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2
We report the characterization of BMS-911543, a potent and selective small-molecule inhibitor of the Janus kinase (JAK) family… 
2012
2012
Abstract 2576: STAT3 tyrosine phosphorylation is frequent in diffuse large B cell lymphoma and is independent of molecular subtype: Implications for biomarker
Diffuse Large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin9s lymphoma, and is associated with variable clinical… 
2011
2011
Targeting the CML Stem/Progenitor Cell with JAK2 (BMS-911543)/ABL Inhibitor Combination Therapy
Abstract 2743 The hallmark of chronic myeloid leukemia (CML) is the BCR-ABL fusion gene that originates in hematopoietic stem… 
2011
2011
Abstract DDT01-03: Discovery of BMS-911543, a highly selective JAK2 inhibitor, as a clinical candidate for the treatment of myeloproliferative disease and other malignancies
Myeloproliferative diseases (MPDs) are a subset of myeloid malignancies that are characterized by the expansion of a multipotent… 
2010
2010
Characterization of BMS-911543, a Functionally Selective Small Molecule Inhibitor of JAK2
Abstract 4112 We report the characterization of BMS-911543, a potent and functionally selective small molecule inhibitor of the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)